Across the nation, Stryker hip lawyers are working hard to assist those who were harmed by the recalled Stryker Rejuvenate or ABGII hip implant. Believing Stryker’s new design to be much safer than other metal-on-metal implants on the market, surgeons, patients and Stryker hip lawyers expected good results. Unfortunately, both models were recalled in July, 2012, with Stryker stating a higher-than-normal risk of fretting and corrosion. This corrosion could, in turn, lead to the release of metal ions and, eventually, total hip failure.

On July 6, 2012, Stryker Orthopedics announced it was recalling its Stryker Rejuvenate and ABGII hip implants and ceasing global production of the two models. Stryker hip attorneys note that at the time of the recall, the company stated there was a higher-than-normal risk of implant failure due to excessive fretting and corrosion. This excess corrosion was found to lead to a release of metal ions into the body. The tiny metal ions which settled around the hip joint resulted in excess inflammation in the area, pain for the patient, tissue and bone degradation, and even total hip failure. Some patients reported to their Stryker hip attorney that groin pain was also experienced.

Many recipients of the Stryker Rejuvenate may well wonder what events led up to the recall of the hip implant device in July, 2012. Was the company aware of the Stryker Rejuvenate design problems prior to releasing the device? Was the propensity for Stryker Rejuvenate fretting known? Was sufficient safety testing done prior to release of the Rejuvenate or was consumer safety sacrificed in favor of a larger profit margin? While the entire truth may never be known, many attorneys and consumers feel that, at the very least, Stryker downplayed the risks of the implant device, even at the time of the recall.

The Stryker Rejuvenate hip implant was recalled by Stryker in July, 2012 after numerous reports came in to the FDA regarding symptoms of metal toxicity and metallosis among recipients. Stryker cited a higher-than-normal rate of failure due to the likelihood of fretting and corrosion, leading to excess metal ion debris generation. The design of the Stryker Rejuvenate was considered extremely innovative at the time it was released. After many recipients of all-metal hip implant devices suffered significant health problems, the ceramic ball of the Rejuvenate was believed to be a safer alternative with fewer risks of metal ion shear

Just nine months ago, Stryker Corp., the manufacturer of the recalled Rejuvenate and ABGII hip implant devices, estimated the costs associated with the recall would likely range between $190 and $390 million. Yet on October 28^th, that estimate jumped to over $1.1 billion, not including the costs associated with patient revision surgeries, testing or additional treatment.  Hundreds of lawsuits have been filed in response to the July, 2012 recall, with hundreds more expected